Second-Line CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Patients with large B-cell lymphoma that is refractory to induction immunochemotherapy or relapses within one year after completion of induction have traditionally undergone a second-line reinduction treatment followed by high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT). However, only a minority of these patients achieve durable remission. In the industry-sponsored, multicenter, phase 3 TRANSFORM trial, researchers compared HDC/ASCT with the CD19-directed CAR T-cell lisocabtagene maraleucel (liso-cel) in patients with diffuse large B-cell lymphoma that progressed within 12 months of completion of initial therapy.

Patients aged 18 to 75 years underwent T-cell collection by leukapheresis prior to randomization to liso…